Are peptides legal in Connecticut?

Can a Connecticut resident get peptides by telehealth?

Section 19a-906 defines telehealth to include synchronous interactions, asynchronous store and forward transfers, and remote patient monitoring, and requires a telehealth provider to meet the same standard of care as in-person care, have access to the patient's relevant medical history, and obtain consent. The statute bars telehealth prescribing of schedule I, II, and III controlled substances except narrow non-opioid psychiatric and substance use disorder cases; peptides in this database are not controlled, so that limit does not affect GLP-1 or compounded peptide prescriptions. The temporary authorization in section 19a-906 that let certain out-of-state providers treat Connecticut patients ran through June 30, 2025, so a prescriber now generally needs a Connecticut license. Because asynchronous care is expressly part of the definition, a non-controlled prescription may follow an asynchronous evaluation that meets the standard of care. [2] [3]

How does the Connecticut pharmacy board treat compounding?

Connecticut regulates pharmacies through the Department of Consumer Protection and the Commission of Pharmacy under chapter 400j of the General Statutes. Connecticut has no separate state bulks list, so peptide eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). Two Connecticut rules matter for injectable peptides. First, a pharmacy outside Connecticut must hold a nonresident pharmacy registration under section 20-627 and disclose whether it dispenses sterile pharmaceuticals into the state. Second, section 20-633b defines a sterile compounding pharmacy to include registered nonresident pharmacies and requires a nonresident applicant that intends to compound sterile products for Connecticut patients to file an addendum, provide proof of a passed home-state inspection, and wait for written approval from the Department and the Commission before shipping. Connecticut's sterile compounding regulations (Regulations of Connecticut State Agencies sections 20-576-64 to 20-576-68, adopted 2011) apply to pharmacies licensed under section 20-594 and require compliance with the current USP chapter 797, a policy and procedure manual that complies with chapter 797, a two-week limit on compounded products supplied to practitioners for office use, and at least 35 open hours a week unless waived. Those regulations do not set separate compounding standards for nonresident pharmacies; a nonresident sterile compounder is governed by the section 20-633b addendum, inspection, and approval process described above. [1] [4] [5] [6] [7] [9]

Can you get compounded GLP-1s in Connecticut?

Because compounded GLP-1 injections are sterile preparations, an out-of-state pharmacy shipping them to Connecticut must have an approved sterile compounding addendum under section 20-633b in addition to its nonresident registration. [5] [6] [12]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Connecticut?

Find a provider in Connecticut

• Compounding pharmacies in Connecticut
• Clinics in Connecticut
• Telehealth providers in Connecticut

Is it legal to buy research peptides in Connecticut?

Only Connecticut-licensed pharmacies and registered nonresident pharmacies may dispense prescription drugs to Connecticut patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and fall outside Connecticut's sterile compounding approval system. Connecticut law also bars the sale directly: under the Connecticut Food, Drug and Cosmetic Act, section 21a-110 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has been approved under section 355 of the federal act or, for a drug not subject to the federal act, a state application has been filed with the Commissioner of Consumer Protection. The Connecticut Attorney General has used the Connecticut Unfair Trade Practices Act (Conn. Gen. Stat. 42-110a and following) against sellers of research-grade GLP-1s, including a 2025 settlement with an online distributor and a May 2026 settlement under which an international online trade platform agreed to stop GLP-1 sales to US consumers and remove such listings. The same May 2026 announcement included a settlement with a medical spa that stopped advertising and prescribing compounded semaglutide and tirzepatide. [5] [8] [13] [14]

Peptide-specific notes for Connecticut

Frequently asked questions

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, and federal FDA guidance.